The Latest Drug Delivery Industry Statistics Explained
The global drug delivery market is expected to reach approximately $1,917.82 billion by 2025 at a CAGR of 10.6% from 2019 to 2025.
The statistic indicates that the global drug delivery market is projected to grow significantly, reaching a value of around $1,917.82 billion by the year 2025. This growth is expected to occur at a compound annual growth rate (CAGR) of 10.6% from 2019 to 2025. The CAGR represents the average annual growth rate of the market during this period. This forecast suggests a strong and sustained increase in the market value over the specified time frame, driven by factors such as advancements in drug delivery technologies, increasing healthcare expenditures, and rising demand for targeted and controlled drug delivery systems.
The North American regional drug delivery systems market dominated the global market, with a share of 45.2% in 2020.
The statistic indicates that in 2020, the North American regional drug delivery systems market accounted for a significant portion of the global market, holding a share of 45.2%. This suggests that North America was the leading region in terms of market size and influence in the drug delivery systems industry. The dominance of the North American market may be attributed to factors such as technological advancements, robust healthcare infrastructure, strong investment in research and development, and high demand for innovative drug delivery solutions in the region. This statistic highlights the importance of North America as a key player in the global market for drug delivery systems.
The nasal drug delivery technology market is expected to reach USD 64.20 Billion by 2021 from USD 44.00 Billion in 2016, at a CAGR of 6.5%.
This statistic indicates the projected growth in the nasal drug delivery technology market from 2016 to 2021. It estimates that the market size will increase from USD 44.00 Billion in 2016 to USD 64.20 Billion by 2021. This represents a Compound Annual Growth Rate (CAGR) of 6.5%, which signifies the average annual growth rate over the specified period. The CAGR of 6.5% suggests that the market is expected to expand steadily during the forecast period. This growth could be driven by factors such as increased adoption of nasal drug delivery systems, advancements in technology, rising prevalence of chronic diseases requiring nasal medication, and growing demand for non-invasive drug delivery methods.
The home care settings segment accounted for the largest market share in 2020, driven by the increasing preference for self-administration.
The statistic indicates that in 2020, the home care settings segment held the largest portion of the market share within a specific industry, likely related to healthcare or pharmaceuticals. This dominance was primarily driven by the growing trend of individuals choosing to administer their own care at home rather than seeking medical assistance in traditional healthcare facilities. This shift in preference may be attributed to various factors such as convenience, comfort, cost-effectiveness, and the desire for greater autonomy in managing one’s health. The data suggests that the demand for home care services is increasing, potentially influencing the overall market landscape and emphasizing the importance of catering to this consumer trend in the industry’s strategies and offerings.
Injectable drug delivery market is to reach US$ 789.7 billion by 2024 from estimated US$ 362.4 million in 2016 with a CAGR of 11.3% during the forecast period from 2018 to 2024.
The statistic provided indicates that the global injectable drug delivery market is poised for significant growth over the forecast period from 2018 to 2024. The market is expected to increase from an estimated value of US$ 362.4 million in 2016 to reach US$ 789.7 billion by 2024, representing a robust compound annual growth rate (CAGR) of 11.3%. This notable growth is driven by various factors such as the increasing prevalence of chronic diseases, advancements in drug delivery technologies, and the rising demand for targeted and sustained-release therapies. The expanding geriatric population and the need for effective drug administration methods further contribute to the expansion of the injectable drug delivery market.
The controlled release drug delivery market segment held the largest revenue share, accounting for over 49.1% of the market in 2020.
In 2020, the controlled release drug delivery market segment emerged as the dominant player in the pharmaceutical industry, capturing a significant revenue share of over 49.1%. This statistic indicates that controlled release drug delivery technologies, which are designed to release drugs into the body in a controlled and sustained manner, have gained widespread popularity and adoption among healthcare providers and patients. The substantial market share held by this segment suggests a growing demand for more efficient and effective drug delivery mechanisms that can enhance treatment outcomes, improve patient compliance, and optimize therapeutic benefits. The dominance of the controlled release drug delivery market segment underscores its importance and potential for further growth and innovation in the pharmaceutical sector.
In 2019, the oral drug delivery segment held a major market share of 52.8% in the global targeted drug delivery system market.
The statistic indicates that in 2019, the oral drug delivery segment dominated the global targeted drug delivery system market by holding a significant market share of 52.8%. This means that more than half of the market for targeted drug delivery systems was comprised of products designed for oral administration. The high market share of oral drug delivery signifies its widespread use and popularity in delivering drugs to targeted areas within the body. This statistic reflects the preference for oral drug delivery methods among patients and healthcare providers, potentially due to factors such as convenience, patient compliance, and effectiveness of targeted drug delivery through this route.
In 2021, the global specialty drug delivery market size was valued at approximately USD 1135 Billion.
The statistic indicates that in the year 2021, the total market size of specialty drug delivery worldwide reached an estimated value of USD 1135 billion. This value reflects the economic significance of the specialty drug delivery sector, which pertains to the development and utilization of advanced methods for delivering complex therapeutics to patients. The size of this market suggests a growing demand for specialized drug delivery technologies and solutions, driven by factors such as the increasing prevalence of chronic diseases, advancements in pharmaceutical research and development, and the need for more targeted and efficient drug administration. Overall, this statistic highlights the substantial market value and potential opportunities within the global specialty drug delivery industry.
The Asia Pacific regional market is expected to grow at a CAGR of 9.0% from 2021 to 2028.
This statistic indicates that the Asia Pacific regional market is projected to experience an average annual growth rate of 9.0% from the year 2021 to 2028. This compound annual growth rate (CAGR) serves as a measure of the smooth annual growth rate that would provide the same cumulative growth as the actual, fluctuating growth rate over a specified period. The reported 9.0% CAGR suggests a sustained and relatively strong growth trajectory for the Asia Pacific regional market over the stated time frame, reflecting positive economic conditions and potentially favorable market dynamics within the region.
Pulmonary drug delivery systems held the second-largest share in 2019 due to a high prevalence of respiratory disorders.
The statistic suggests that pulmonary drug delivery systems accounted for the second-largest share of the market in 2019, primarily driven by the high prevalence of respiratory disorders. This indicates that a significant portion of the population suffers from respiratory conditions, such as asthma, chronic obstructive pulmonary disease (COPD), and cystic fibrosis, among others, creating a demand for effective treatment options delivered directly to the lungs. As a result, pharmaceutical companies and healthcare providers are focusing on developing and promoting inhalation therapies and devices to cater to the needs of patients with respiratory disorders, leading to the notable market share held by pulmonary drug delivery systems in 2019.
The demand for biosimilar drugs is developing at a considerable rate, with a projected CAGR of 31.7% from 2020 to 2027.
The statistic that the demand for biosimilar drugs is growing at a substantial rate, with a projected compound annual growth rate (CAGR) of 31.7% from 2020 to 2027, indicates a significant and rapid expansion in the market for these pharmaceutical products. The CAGR of 31.7% suggests that the demand for biosimilar drugs is expected to almost triple every year during this period. This remarkable growth rate is likely driven by various factors such as increasing healthcare costs, patent expirations of biologic drugs, and the need for more affordable treatment options. The projection highlights a strong market potential for biosimilar drugs and underscores their growing importance in the healthcare industry.
The European Market is predicted to reach USD 536.1 billion by 2027.
This statistic indicates that the overall value of the European Market is expected to increase significantly and reach a total of USD 536.1 billion by the year 2027. This prediction suggests positive growth and expansion in the European market, signifying potential opportunities for businesses and investors to capitalize on. Factors such as economic stability, consumer demand, technological advancements, and market trends are likely to contribute to this projected growth. Monitoring these developments and staying informed about key drivers shaping the European market will be essential for stakeholders looking to navigate this evolving landscape successfully.
The Self-injection devices segment in the industry is expected to expand at a CAGR of over 10.9% during 2021-2028.
This statistic indicates that the market for self-injection devices within the industry is anticipated to experience substantial growth over the period from 2021 to 2028, with a Compound Annual Growth Rate (CAGR) exceeding 10.9%. This suggests a consistent and strong upward trend in the demand for self-injection devices, likely driven by factors such as advancements in healthcare technology, increasing prevalence of chronic diseases requiring self-administered treatments, and a growing preference for convenience and ease of use among patients. Such rapid expansion in the market for self-injection devices signals significant opportunities for companies operating in this sector to capitalize on the increasing demand and potentially achieve higher revenue and market share in the coming years.
Latin America drug delivery market size exceeded USD 24 billion in 2020 and is estimated to grow at over 9.3% CAGR between 2021 and 2027.
The statistic indicates that the Latin America drug delivery market reached a size of over USD 24 billion in the year 2020. It is further projected to experience rapid growth at a compound annual growth rate (CAGR) exceeding 9.3% from the year 2021 to 2027. This growth trend suggests a significant increase in the consumption and demand for drug delivery technologies and services within the Latin American region over the forecasted period. Factors driving this growth could include advancements in healthcare infrastructure, rising prevalence of chronic diseases, and increasing investments in pharmaceutical research and development within the region.
In 2019, the pharmaceutical companies end-use segment led the market and accounted for 28.0% share of the global revenue.
The statistic means that in 2019, the pharmaceutical companies’ end-use segment was the leading contributor to the global market revenue, comprising 28.0% of the total revenue generated by the industry. This indicates the significant influence and dominance of pharmaceutical companies in the market during that year. The high share of revenue highlights the importance and reliance on the products and services provided by pharmaceutical companies, emphasizing their strong position in the industry. This statistic underscores the crucial role that pharmaceutical companies play in driving the overall market performance and demonstrates their substantial contribution to the global economy.
In the transmucosal drug delivery segment, the oral thin film (OTF) category held the largest share of 32.5% in 2020.
In the transmucosal drug delivery segment, the statistic indicates that the oral thin film (OTF) category accounted for the highest proportion of market share at 32.5% in 2020. This suggests that OTF products, which are typically thin, dissolvable films placed on the oral mucosa for drug delivery, were the most popular choice among consumers or healthcare providers in that year. The significance of this statistic lies in highlighting the dominance of OTF products in the transmucosal drug delivery market, indicating their widespread acceptance and utilization compared to other modes of drug administration within this segment. Companies operating in this market may use this information to inform their product development, marketing strategies, and investment decisions to capitalize on the growing demand for oral thin film drug delivery systems.
Inhaled Drug Delivery Devices market size will grow from USD 13.1 Billion in 2017 to USD 19.6 Billion by 2023, at an estimated CAGR of 7%.
The statistic indicates that the market size of Inhaled Drug Delivery Devices is expected to increase from USD 13.1 Billion in 2017 to USD 19.6 Billion by the year 2023, representing a Compound Annual Growth Rate (CAGR) of 7%. This growth projection suggests a steady and significant expansion in the market over the specified period. The increasing demand for inhaled drug delivery systems, advancements in technology, rising prevalence of respiratory diseases, and the growing aging population can be some of the key factors contributing to this projected market growth. The CAGR provides a measure of the average annual growth rate of the market, indicating a promising outlook for the inhaled drug delivery devices industry.
Conclusion
Overall, the drug delivery industry is a dynamic and continuously evolving field with a promising future. By examining the statistics and trends outlined in this post, it is evident that advancements in drug delivery technology are driving innovation and improving patient outcomes. As the industry continues to grow and adapt to new challenges, stakeholders should stay informed and collaborate to ensure the safe and efficient delivery of life-saving medications.
References
0. – https://www.www.grandviewresearch.com
1. – https://www.www.gminsights.com
2. – https://www.reports.valuates.com
3. – https://www.www.polarismarketresearch.com
4. – https://www.marketdesk.org
5. – https://www.www.prnewswire.com
6. – https://www.www.marketsandmarkets.com
7. – https://www.www.globenewswire.com
8. – https://www.www.fortunebusinessinsights.com
9. – https://www.www.researchandmarkets.com
10. – https://www.www.emergenresearch.com
11. – https://www.www.graphicalresearch.com
12. – https://www.www.transparencymarketresearch.com
